secwatch.observer — SEC 8-K summary
======================================

Issuer:     ZyVersa Therapeutics, Inc. (ZVSA)
CIK:        0001859007
Form:       8-K
Filed at:   2022-12-13T23:59:59+00:00
Accession:  0001493152-22-035258
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.95
Item codes: 1.01, 2.01, 5.06, 9.01, 5.02, 3.02, 4.01, 3.01, 3.03, 5.03, 5.01, 5.05, 8.01
LLM model:  deepseek-v4-flash:cloud@v2

ZyVersa Therapeutics completes de-SPAC merger with Larkspur; 99% of public shares redeemed
--------------------------------------------------------------------------------

- Larkspur merged with ZyVersa on Dec 12, 2022; name changed to ZyVersa Therapeutics, Inc. (ZVSA).
- Public stockholders redeemed 7,667,029 shares (~$77.99M) at $10.17/share, leaving ~100K public shares.
- PIPE investment of $8.635M via Series A Preferred and warrants at $1,000 per unit, conversion price $10.
- Post-deal: 9,081,922 common shares outstanding; exchange ratio of 5.037 for Old ZyVersa shares.
- Ownership: Larkspur Health LLC (16.8%), INCON Co., Ltd. (20.4%), Stephen Glover (15.1%), Daniel O'Connor (16.8%).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1859007/000149315222035258/0001493152-22-035258-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1859007/000149315222035258/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-22-035258

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer